Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs.
Asianet Newsable on MSN13d
Early Signs of Osteoporosis: How to protect your bones before it's too lateOsteoporosis is a medical condition in which new calcium deposits in bone tissue cannot keep up with old bone calcium removal ...
In one of the first studies of its kind, a team of researchers from Keck School of Medicine of USC has found that proteins ...
The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion ...
Should you take a calcium supplement? And if so, how much? Here's what to know about calcium's benefits and some warnings.
Since you can’t see your bones aging, you should be proactive about preventing osteoporosis. Atrium Health’s Fracture ...
A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...
The "Osteoporosis_Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Osteoporosis Clinical ...
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback